For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Adipotide: origin, structure and research history

Research Library › Mitochondrial & Coenzyme

Adipotide, also called prohibitin-targeting peptide 1 (prohibitin-TP01), is a synthetic two-part peptide that joins a homing sequence for prohibitin on the blood vessels of white adipose tissue to a pro-apoptotic sequence. It was created by Mikhail Kolonin, Renata Pasqualini and Wadih Arap at the University of Texas M.D. Anderson Cancer Center and first reported in 2004. As of 22 Oct 2026 it is not approved anywhere, and its clinical development is listed as discontinued.

Key facts

TypeSynthetic, designed two-part (chimeric) peptide
Also known asProhibitin-targeting peptide 1; prohibitin-TP01
First described2004, Nature Medicine (Kolonin, Pasqualini, Arap et al.)
Developed byUniversity of Texas M.D. Anderson Cancer Center, with Baylor College of Medicine; later Ablaris Therapeutics
Designed targetProhibitin on the vascular endothelium of white adipose tissue
Regulatory status (Oct 2026)Not FDA-approved; not approved elsewhere; phase 1 terminated 2019; development discontinued

Who developed it

Adipotide was built by Mikhail Kolonin, Renata Pasqualini and Wadih Arap at the University of Texas M.D. Anderson Cancer Center in Houston, working with colleagues at Baylor College of Medicine. The team’s first report appeared in Nature Medicine in 2004 [1].

Pasqualini and Arap later led a primate study published in 2011 and advanced the compound with the company Ablaris Therapeutics [2][3].

What it was designed to target

Adipotide does not copy any natural hormone. It is a designed peptide with two functional parts. The first is a homing sequence that binds prohibitin, a protein the M.D. Anderson group identified on the surface of blood vessels supplying white fat. The second is a sequence designed to trigger programmed cell death (apoptosis) in the cells it reaches [1][2].

The homing sequence was found by screening very large peptide libraries inside living mice and keeping only the sequences that accumulated in the vasculature of white adipose tissue, an approach known as in vivo phage display [1]. Because the homing and cell-death parts are linked in a single molecule, the design was meant to confine activity to the targeted vessels. It has been tested in mice and monkeys only, never established in people [1][2].

Why it was created

The M.D. Anderson group came to the project from cancer research, where cutting off a tissue’s blood supply is a long-studied strategy. They applied the same vascular-targeting idea to adipose tissue, and adipotide was originally investigated in a research program on obesity [1].

The 2011 primate study also documented kidney changes that grew with exposure, most of which were reversible. That finding became an important safety consideration for the program and was one of the questions an early human study needed to address [2][3].

Research timeline

  • 2004: Kolonin, Pasqualini, Arap and colleagues report the prohibitin-targeting peptide in mice in Nature Medicine [1].
  • 2011: A study in obese rhesus monkeys is published in Science Translational Medicine [2].
  • 2010s: A U.S. phase 1 trial begins in a research program on obesity [3].
  • Jan 2019: The phase 1 trial is terminated at the investigators’ request [3].
  • Today: Development is listed as discontinued [3].

Regulatory status as of October 2026

As of 22 Oct 2026, adipotide is not FDA-approved and has no approval in any other country. Its only human trial, a U.S. phase 1 study, was terminated in January 2019, and the drug-development database AdisInsight lists the program as discontinued [3].

Adipotide was not among the peptides FDA moved off its Category 2 list in April 2026, nor among those voted on by the Pharmacy Compounding Advisory Committee in July 2026 [4][5].

It is not named on the 2026 World Anti-Doping Agency Prohibited List; because it has no approval anywhere, the S0 (non-approved substances) category may apply [6].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who invented adipotide?

Adipotide was created by Mikhail Kolonin, Renata Pasqualini and Wadih Arap at the University of Texas M.D. Anderson Cancer Center, who first reported it in Nature Medicine in 2004.

Is adipotide FDA approved?

No. As of 22 Oct 2026 adipotide is not approved anywhere. Its phase 1 trial was terminated in January 2019 and development is listed as discontinued.

What does adipotide target?

It was designed to bind prohibitin, a protein found on the blood vessels that supply white adipose tissue, and to deliver a sequence that triggers programmed cell death.

What is prohibitin-TP01?

Prohibitin-TP01, or prohibitin-targeting peptide 1, is another name for adipotide used in drug-development records.

Sources

  1. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine. 2004;10(6):625–632. Link
  2. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112. Link
  3. AdisInsight. Prohibitin targeting peptide 1 (adipotide; prohibitin-TP01): drug profile. Link
  4. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 list. 16 Apr 2026. Link
  5. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  6. World Anti-Doping Agency. 2026 Prohibited List (in force 1 Jan 2026): S0. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top